Trial Profile
A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Aldoxorubicin (Primary)
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors LadRx Corporation
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Apr 2012 Status changed from not yet recruiting to recruiting based on information reported in a CytRx Corporation media release.